Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study Shows Aspirin Use By Asian Women Lowers Lung Cancer Risk

This article was originally published in PharmAsia News

Executive Summary

A study of more than 1,000 Asian women concluded they had a decreased risk of lung cancer if they took aspirin at least twice a week, regardless of whether they smoked.

A study of more than 1,000 Asian women concluded they had a decreased risk of lung cancer if they took aspirin at least twice a week, regardless of whether they smoked. The published study by Singapore-based researchers noted no proof was shown that aspirin provides a direct protection against the cancer. The study backed several previous studies showing links between regular aspirin use and the risk of several cancers, including colon, esophageal and prostate cancers. The study included 398 Chinese women diagnosed with lung cancer and 814 without. (Click here for more)

“Aspirin Tied To Lower Lung-Cancer Risk In Women: Study” Reuters (12/24/12)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC080910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel